Combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction

Clinical Governance: An International Journal

ISSN: 1477-7274

Article publication date: 8 August 2008

Citation

(2008), "Combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction", Clinical Governance: An International Journal, Vol. 13 No. 3. https://doi.org/10.1108/cgij.2008.24813cae.010

Publisher

:

Emerald Group Publishing Limited

Copyright © 2008, Emerald Group Publishing Limited


Combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction

Article Type: Reviews of effectiveness From: Clinical Governance: An International Journal, Volume 13, Issue 3

C.O. Phillips, A. Kashani, D.K. Ko, G. Francis and H.M. Krumholz, (2007), “Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials”

Archives of Internal MedicineVol. 167 No. 18pp. 1930-6

This review, which evaluated the safety of combination angiotensin II-receptor blockers (ARBs) plus angiotensin-converting enzyme (ACE) inhibitors in symptomatic left ventricular dysfunction, concluded that ARB plus ACE inhibitor therapy is associated with a significant increase in the risks of medication nonadherence, renal dysfunction and symptomatic hypotension. The authors’ overall conclusions appear to reflect the evidence presented and are likely to be reliable, but it should be noted that the evidence was based on a small number of trials only.